Wayne Carter

Wayne Carter

University of Nottingham, UK

Title: Detection and identification of novel biomarkers of exposure to pesticides


Wayne Grant Carter received his Honours degree in Biochemistry with Nutrition from the University of Southampton. He then completed a Ph.D. at the University of Southampton studying the molecular signalling cascade elicited by insulin (Carter et al., 1995, Asamoah et al., 1995; Carter et al., 1996) supervised by Dr. Graham Sale. Dr. Carter then moved to the Babraham Institute, Cambridge, to work with Professor Jeremy Saklatvala, on studies to elucidate the signalling mechanisms activated as a response to pro-inflammatory cytokines (Finch et al., 2001). Dr. Carter then relocated with Professor Saklatvala's group to the Kennedy Institute of Rheumatology, part of Imperial College, London. Subsequently, Dr. Carter moved to the University of California at Irvine to work with Professor Dana Aswad, similarly studying protein post-translational modification, and protein damage and repair (Young et al., 2001). Dr. Carter then joined the Department of Human Anatomy & Genetics headed by Professor Kay Davies CBE FRS at the University of Oxford, before moving to take up an industrial post with Mobious Genomics, Exeter. He is currently an Editorial Board member of the BIOINFO Journal of Proteomics; Current Chemical Research; Journal of Analytical Sciences, Methods and Instrumentation; World Journal of Biological Chemistry; and Executive Editor for Europe for Journal of Chromatography and Separation Techniques.


A biological biomarker may provide a valuable means to detect, measure, or quantify normal biological activity or that associated with a disease, or assess the effects of a disease treatment. Differential proteome profiling is often used to provide a basis for mining suitable biomarkers of disease. However, patho-physiological changes may be manifested as either a difference in protein post-translational modification (PTM) levels and/or alteration in protein associations. These processes may arise in the absence of protein level changes, and may therefore be missed by conventional biomarker proteomics. We have assessed protein PTM in the cerebro spinal fluid of multiple sclerosis (MS) patients and control subjects. We report the detection of novel protein biomarkers in MS patients via radiolabelling of PTMs. The sensitivity afforded by protein PTM radiolabelling and autoradiography provided a basis to detect novel protein biomarkers, and characterise the proteins by one dimensional and two dimensional separation techniques. This sensitivity and detection of protein PTM provided a viable means to track these novel biomarkers, and enable purification to a level sufficient for mass spectrometry identification